BeiGene (BGNE +0.3%) inks an agreement with EUSA Pharma for exclusive rights to Sylvant (siltuximab) in Greater China and Qarziba (dinutuximab beta) in Mainland China.
BGNE will be responsible for all clinical development, regulatory filings and commercialization in the territories. EUSA will receive an upfront payment, up to $160M in milestones and tiered royalties on net sales.
Sylvant is currently approved in over 40 countries for a rare lymph node disorder called Castleman disease.
Qarziba is currently approved in Europe for neuroblastoma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.